Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
394 studies found for:    myelodysplastic syndromes | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Procedure: Best Supportive Care;   Drug: BI 836858
22 Recruiting A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: OPN-305
23 Recruiting An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: epoetin beta [Recormon]
24 Recruiting CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Condition: Previously Treated Myelodysplastic Syndromes
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
25 Recruiting A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Luspatercept;   Other: Placebo
26 Recruiting A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Condition: Myelodysplastic Syndrome
Interventions: Procedure: Bone marrow aspirate;   Drug: Deferasirox
27 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
28 Recruiting A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Azacitidine
29 Recruiting Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Conditions: Adult Patients With Low Risk Myelodysplastic Syndrome;   Adult Patients With Int 1-risk Myelodysplastic Syndrome
Interventions: Drug: Erythropoietin alpha;   Drug: Deferasirox
30 Recruiting Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: selinexor (KPT-330)
31 Recruiting Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Condition: Myelodysplastic Syndromes
Interventions: Drug: Eltrombopag/Revolade;   Other: Placebo;   Drug: Lenalidomide
32 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
33 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
34 Recruiting The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine;   Drug: Placebo
35 Recruiting A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: No interventions
36 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
37 Not yet recruiting Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
38 Recruiting Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes;   Anemia
Intervention: Drug: Pegol-sihematide injection
39 Not yet recruiting Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Conditions: Anemia;   Myelodysplastic Syndrome
Interventions: Drug: Deferasirox;   Other: Laboratory Biomarker Analysis
40 Recruiting A Dose Escalation and Cohort Expansion Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Intervention: Drug: TEN-010

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.